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Tumorigenic Effect of Some Commonly Used
Moisturizing Creams when Applied Topically to
UVB-Pretreated High-Risk Mice
Yao-Ping Lu1, You-Rong Lou1, Jian-Guo Xie1, Qingyun Peng1, Weichung J. Shih2,3, Yong Lin2,3 and
Allan H. Conney1,3
Irradiation of SKH-1 mice with UVB (30mJ cm2) twice a week for 20 weeks resulted in mice with a high risk of
developing skin tumors over the next several months in the absence of further irradiation with UVB (high-risk
mice). Topical applications of 100mg of Dermabase, Dermovan, Eucerin Original Moisturizing Cream (Eucerin),
or Vanicream once a day, 5 days a week for 17 weeks to these high-risk mice increased significantly the rate of
formation of tumors and the rate of increase in tumor size per mouse. Additional studies indicated that
treatment of high-risk mice with Dermabase, Dermovan, Eucerin, or Vanicream for 17 weeks increased the total
number of histologically characterized tumors by 69% (average of two experiments; Po0.0001 in each
experiment), 95% (Po0.0001), 24% (Po0.01), and 58% (Po0.0001), respectively. Topical applications of a specially
designed Custom Blend cream to high-risk mice was not tumorigenic. The results indicate that several
commercially available moisturizing creams increase the rate of formation and number of tumors when applied
topically to UVB-pretreated high-risk mice. Further studies are needed to determine the effects of topical
applications of moisturizing creams on sunlight-induced skin cancer in humans.
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INTRODUCTION
Sunlight-induced nonmelanoma skin cancer is the most
prevalent cancer in the United States, with more than one
million cases per year (almost as many cases as for all of the
other cancers combined; Scotto et al., 1996; Jemal et al., 2008).
The incidence of these cancers is increasing, which is believed
to be caused by the aging population, increased recreational
exposure to sunlight, decreased clothing coverage, and the
depletion of the atmospheric ozone layer (McKenzie et al.,
1999; Wassberg et al., 2001; de Gruijl et al., 2003; Diffey,
2004; de Vries et al., 2006; Kojo et al., 2006; Norval et al.,
2007; Ridky, 2007; Christenson et al., 2008). Although most
nonmelanoma skin cancers (basal cell and squamous cell
carcinomas) can be detected early and are cured by surgical
removal, some people still die from these cancers—particularly
from squamous cell carcinomas. Because of the prevalence of
sunlight-induced skin cancer, factors that influence the
incidence of these cancers are of considerable importance.
Recent research on UV carcinogenesis and factors influencing
UV carcinogenesis are described in a special issue of
Photochemistry and Photobiology (vol. 84, March/April 2008).
Large numbers of people worldwide are using moisturiz-
ing creams and ointments topically, but to the best of our
knowledge most of these creams/ointments have not been
tested for carcinogenic activity during the course of UVB
irradiation in animals or when applied topically to UVB-
pretreated animals after stopping irradiation with UVB in a
model that resembles humans who receive extensive
exposure to sunlight early in life and develop skin cancers
later in life in the absence of further heavy exposure to
sunlight. In earlier studies, we developed a mouse model for
sunlight-induced skin cancer in humans by irradiating SKH-1
hairless mice with UVB (30mJ cm2) twice a week for 20
weeks and then stopping UVB irradiation (Lou et al., 1999).
These mice have a high risk of developing squamous cell
papillomas, keratoacanthomas, and squamous cell carcino-
mas during the next several months in the absence of further
UVB irradiation (high-risk mice; Lou et al., 1999).
In recent studies, we found that oral administration of
caffeine or topical applications of caffeine or caffeine sodium
benzoate enhanced UVB-induced apoptosis (Lu et al., 2000,
2002a, 2007) and inhibited carcinogenesis in UVB-pretreated
high-risk mice in the absence of further UVB treatment
(Lou et al., 1999; Lu et al., 2002b). Topical applications of
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caffeine also enhanced apoptosis in skin tumors in tumor-
bearing mice (Lu et al., 2002b). Since our studies suggested
the possible utility of caffeine and caffeine sodium benzoate
as topical agents for inhibiting sunlight-induced skin cancer
in humans, we started planning for human studies and
initially selected Dermabase (the constituents in Dermabase
and the other creams/ointments used in this study are given in
Table 1) as a vehicle for topical caffeine studies in humans.
However, we felt that it would be prudent to test Dermabase
for carcinogenic activity before doing extensive studies in
humans. Accordingly, we tested Dermabase for carcinogenic
activity in UVB-pretreated SKH-1 mice that have no tumors
but have a high risk of developing tumors after stopping UVB
(high-risk mice).
Our initial study indicated that Dermabase was carcino-
genic when applied topically once a day, 5 days a week for
17 weeks to UVB-pretreated high-risk mice after stopping
UVB irradiation. Because of the carcinogenic activity of
Dermabase in high-risk mice, we decided to test other
commonly used moisturizing creams for tumorigenic activity
as well as to develop a novel Custom Blend cream (The
Custom Blend cream was prepared with the help of Johnson
and Johnson Consumer and Personal Products Worldwide
(Skillman, NJ)) that we hoped would not have tumorigenic
activity. Substances that we worried about that were
excluded from the Custom Blend cream at our request and
prepared by Johnson and Johnson included sodium lauryl
sulfate (an irritant; Bock et al., 2007; Slotosch et al., 2007)
and mineral oil (a stimulator of UVB tumorigenesis; Kligman
and Kligman, 1992). The present report describes the effects
of topical applications of Dermabase, Dermovan, Eucerin
Original Moisturizing Cream (Eucerin), Vanicream, and the
Custom Blend cream on the formation of skin tumors in UVB-
pretreated mice that have a high risk for developing skin
tumors in the absence of further irradiation with UVB (high-
risk mice). The constituents in these moisturizing creams,
which are oil in water emulsions, are described in Table 1.
RESULTS
Experiment 1
Treatment of UVB-pretreated high-risk mice with 100mg of
Dermabase topically once a day, 5 days a week for 17 weeks
increased the rate of increase in the formation of tumors per
mouse (Po0. 001) and tumor volume per mouse (P¼0.023)
when compared with untreated control mice during the
17-week treatment period (Figure 1a).
Histology studies showed that topical applications of
Dermabase to high-risk mice for 17 weeks increased the total
number of tumors per mouse by 79% (Po0.0001), the
number of keratoacanthomas per mouse by 77%
(Po0.0001), and the number of squamous cell carcinomas
per mouse by 127% (P¼ 0.021) when compared with
untreated control high-risk mice (Table 2). The percentage
of mice with squamous cell carcinomas was increased by
Table 1. Ointments and creams studied (oil in water emulsions)
Dermabase cream
Paddock Laboratories Inc. (Minneapolis, MN)
Ingredients:
Purified water, mineral oil, petrolatum, cetostearyl alcohol, propylene glycol, sodium lauryl sulfate, isopropyl palmitate, imidazolidinyl urea,
methylparaben, and propylparaben.
Dermovan
Healthpoint Ltd. (Fort Worth, TX)
Ingredients:
Water, glyceryl stearate (and) stearamidoethyl diethylamine, glycerin, mineral oil, cetyl esters, cetyl alcohol, butylparaben, methylparaben, and
propylparaben.
Eucerin Original Moisturizing Cream (Eucerin)
Beiersdorf Inc. (Wilton, CT)
Ingredients:
Water, petrolatum, mineral oil, ceresin, lanolin alcohol, methylchloroisothiazolinone, and methylisothiazolinone
Vanicream
Pharmaceutical Specialties Inc. (Rochester, MN)
Ingredients:
Purified water, white petrolatum, cetearyl alcohol and ceteareth-20, sorbitol solution, propylene glycol, simethicone, glyceryl monostearate,
polyethylene glycol monostearate, sorbic acid, and BHT.
Custom Blend
Johnson and Johnson Skin Research Center (Skillman, NJ)
Ingredients:
Purified water, propylene glycol, stearyl alcohol, cetyl alcohol, polysorbate 20, isopropyl myristate, C12-15 alkyl benzoate, benzoic acid, glycerin,
and sodium hydroxide (final pH=5.8)
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Figure 1. Time course for the effect of topical applications of different moisturizing creams on the formation of tumors in ‘‘high-risk’’ mice pretreated with
UVB. Female SKH-1 hairless mice were treated with UVB (30mJ cm2) twice a week for 20 weeks to obtain tumor-free ‘‘high-risk’’ mice. The mice were
then untreated, treated topically with water (100ml) or with the indicated cream (100mg) once a day, 5 days a week for 17 weeks in the absence of further
treatment with UVB. The data are expressed as the mean±SE. Statistical analyses of differences in pair-wise regression slopes of rates of change with time
were determined for tumors per mouse and for tumor volume per mouse as described in the Materials and Methods section. The statistical analysis of
changes in the percent of mice with tumors versus time was based on a comparison of tumor-free distribution between the two groups by the log-rank test
as described in the Materials and Methods section. Statistically significant differences from the water-treated control group (Po0.05) are indicated.
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108% (P¼ 0.043) in the Dermabase-treated group (Table 2).
Treatment of the mice with Dermabase increased the average
tumor volume per mouse by 136% for total tumors, 64% for
keratoacanthomas, and 262% for squamous cell carcinomas
(Table 3). Tumor volume per mouse for all nonmalignant
tumors was increased 63% (Po0.05; Table 3).
Experiment 2
Water control versus untreated. Treatment of UVB-pre-
treated high-risk mice with 100 ml of water topically once a
day, 5 days a week for 17 weeks did not have an effect on the
rate or extent of tumor formation during the 17-week
treatment period (Figure 1b) or on the formation or size of
histologically defined tumors (Tables 4 and 5) when
compared with untreated high-risk mice. Because the
untreated and water-treated control groups were not
different, they were combined into a single control group
for the histology studies.
Studies with Dermabase. In the second experiment,
topical applications of 100mg of Dermabase once a day,
5 days a week to high-risk mice increased the rate of increase
in the percent of mice with tumors (P¼0.003), tumors
per mouse (Po0.0001), and tumor volume per mouse
(P¼0.032) when compared with control mice treated
topically with water during the 17-week treatment period
(Figure 1c).
Histology studies indicated that topical applications of
Dermabase for 17 weeks to high-risk mice in experiment 2
increased the number of keratoacanthomas per mouse by
62% (Po0.0001), the number of squamous cell carcinomas
per mouse by 26%, and the total number of histologically
characterized tumors per mouse by 59% (Po0.0001) when
compared with the combined control group (Table 4).
Treatment of the mice with Dermabase increased the average
tumor volume per mouse (for all mice) by 64% when
compared with the combined control group (Table 5).
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Figure 1. Continued.
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Studies with Dermovan. Treatment of high-risk mice with
100mg of Dermovan topically once a day, 5 days a week for
17 weeks increased the rate of increase in the percent of mice
with tumors (P¼ 0.01), tumors per mouse (Po0.0001), and
tumor volume per mouse (Po0.0001) when compared with
the control high-risk mice treated topically with water during
the 17-week treatment period (Figure 1d).
Histology studies indicated that treatment of the high-risk
mice with Dermovan for 17 weeks increased the percentage of
mice with squamous cell papillomas by 342% (Po0.05), the
number of squamous cell papillomas per mouse by 244%, the
number of keratoacanthomas per mouse by 90% (Po0.0001),
and the number of squamous cell carcinomas per mouse by
137% when compared with the combined control group
(Table 4). The total number of histologically characterized
tumors per mouse was increased 95% (Po0.0001; Table 4).
Treatment of the mice with Dermovan increased the average
tumor volume per mouse (for all mice) by 88% (Table 5).
Studies with Eucerin. Treatment of high-risk mice topically
with 100mg of Eucerin once a day, 5 days a week for 17 weeks
increased the rate of increase in the number of tumors per
mouse (P¼ 0.0005) and tumor volume per mouse (Po0.0001)
when compared with the water control group (Figure 1e).
Histology studies indicated that topical treatment of high-risk
mice with Eucerin for 17 weeks increased the number of
keratoacanthomas per mouse by 21%, the number of squamous
cell carcinomas per mouse by 100%, and the total number of
histologically characterized tumors per mouse by 24% (Po0.01)
when compared with the combined control high-risk group
(Table 4). Treatment of the mice with Eucerin increased the
average size of tumors per mouse (for all mice) by 49% (Table 5).
Studies with Vanicream. Treatment of high-risk mice with
100mg of Vanicream topically once a day, 5 days a week for
17 weeks increased the rate of increase in the number of
tumors per mouse (Po0.0001) and the tumor volume per
mouse (P¼0.013) when compared with the water control
group (Figure 1f).
Histology studies indicated that treatment of high-risk
mice with Vanicream for 17 weeks increased the number of
squamous cell papillomas per mouse by 89%, the number of
keratoacanthomas per mouse by 61% (Po0.0001), and the
total number of histologically characterized tumors per
mouse by 58% (Po0.0001) when compared with the
combined control group (Table 4). Treatment of the mice
with Vanicream increased the average tumor size per mouse
(for all mice) by 58% (Table 5).
Table 2. Effect of topical applications of Dermabase cream on the incidence and multiplicity of histologically
characterized skin tumors in high-risk SKH-1 mice previously treated with UVB light (exp. 1)
Squamous cell
papillomas Keratoacanthomas
Total nonmalignant
tumors
Squamous cell
carcinomas Total tumors
Treatment
No.
of
mice
Percent of
mice with
tumors
Tumors
per mouse
Percent of
mice with
tumors
Tumors
per mouse
Percent of
mice with
tumors
Tumors
per mouse
Percent of
mice with
tumors
Tumors
per mouse
Percent of
mice with
tumors
Tumors
per mouse
Untreated 29 10 0.10±0.06 86 6.41±1.16 86 6.52±1.19 24 0.41±0.15 86 6.93±1.28
Dermabase 28 7 0.11±0.08 96 11.36±1.371
(77)
96 11.46±1.391
(76)
502
(108)
0.93±0.222
(127)
96 12.39±1.531
(79)
Female SKH-1 mice (7- to 8-week old) were irradiated with UVB (30mJ cm2) twice weekly for 20 weeks, and UVB irradiation was stopped. These tumor-
free mice with a high risk of developing skin tumors were untreated or treated topically with 100mg of Dermabase cream once a day, 5 days a week for
17 weeks. The mice were killed at 18 weeks after the last dose of UVB, and all tumors were characterized by histopathology studies. Each value is the
mean±SE, and the numbers in parentheses represent percent increase. Statistical analysis was done as described in the Materials and Methods section.
Statistically different from the untreated control group (1Po0.0001, 2P=0.021).
Table 3. Effect of topical applications of Dermabase cream on the size of tumors in high-risk SKH-1 mice previously
treated with UVB light (exp. 1)
Squamous cell
papillomas Keratoacanthomas
Total nonmalignant
tumors
Squamous cell
carcinomas Total tumors
Treatment
No. of
mice
Tumor volume
per mouse (mm3)
Tumor volume
per mouse (mm3)
Tumor volume
per mouse (mm3)
Tumor volume
per mouse (mm3)
Tumor volume
per mouse (mm3)
Untreated 29 2.1±1.8 29.9±9.5 32.0±9.9 18.8±8.1 50.8±14.7
Dermabase 28 3.1±2.8 48.9±10.6 52.0±11.9 68.0±24.5 120.0±33.0
(48) (64) (63) (262) (136)
Female SKH-1 mice (7-to 8-week old) were irradiated with UVB (30mJ cm2) twice weekly for 20 weeks, and UVB irradiation was stopped. These tumor-
free mice with a high risk of developing skin tumors were untreated or treated topically with 100mg of Dermabase cream once a day, 5 days a week for
17 weeks. The mice were killed at 18 weeks after the last dose of UVB, and all tumors were characterized by histopathology studies (Table 2) and the size of
each tumor was determined. Each value is the mean±SE, and the numbers in parentheses represent percent increase. None of the increases in tumor volume
per mouse was statistically significant except for the increase in tumor volume per mouse for total nonmalignant tumors in the Dermabase group (Po0.05)
when analyzed by a nonparametric method as described in the Materials and Methods section.
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Table 4. Effect of topical applications of different creams and ointments on the incidence and multiplicity of
histologically characterized skin tumors formed in high risk SKH-1 mice previously treated with UVB light (exp. 2)
Squamous cell papillomas Keratoacanthomas Total nonmalignant tumors Squamous cell carcinomas Total tumors
Treatment
No.
of mice
Percent
of mice
with
tumors
Tumors
per mouse
Percent
of mice
with tumors
Tumors
per mouse
Percent
of mice
with
tumors
Tumors
per
mouse
Percent
of mice
with
tumors
Tumors
per mouse
Percent
of mice
with
tumors
Tumors
per mouse
Water 30 6.7 0.07±0.05 77 4.30±1.12 77 4.37±1.14 17 0.20±0.09 77 4.57±1.21
Untreated 27 7.4 0.11±0.08 85 4.63±0.94 85 4.74±0.99 15 0.19±0.09 85 4.93±1.03
Combined control 57 7.0 0.09±0.04 81 4.46±0.28 81 4.54±0.20 16 0.19±0.06 81 4.74±0.20
Dermabase 29 6.9 0.07±0.05 90 7.21±1.151 90 7.28±1.151 21 0.24±0.09 90 7.52±1.181
(0) (22) (11) (62) (11) (60) (31) (26) (11) (59)
Dermovan 29 31.02 0.31±0.093 86 8.48±1.641 90 8.79±1.651 31 0.45±0.16 90 9.24±1.711
(342) (244) (6) (90) (11) (94) (94) (137) (11) (95)
Eucerin 29 10.3 0.14±0.08 79 5.38±1.18 79 5.52±1.222 21 0.38±0.15 79 5.90±1.333
(47) (56) (2) (21) (2) (22) (31) (100) (2) (24)
Vanicream 30 13.3 0.17±0.08 83 7.17±1.801 83 7.33±1.833 17 0.17±0.07 83 7.50±1.851
(90) (89) (2) (61) (2) (61) (6) (11) (2) (58)
Custom Blend 25 4.0 0.04±0.04 72 4.68±1.13 72 4.72±1.13 12 0.16±0.09 72 4.88±1.19
(43) (56) (11) (5) (11) (4) (25) (16) (11) (3)
In experiment 2, female SKH-1 mice (7- to 8-week old) were irradiated with UVB (30mJ cm2) twice weekly for 20 weeks, and these tumor-free mice with a
high risk of developing skin tumors were untreated or treated topically with 100 ml of water or 100mg of different types of creams or ointments once a day, 5
days a week for 17 weeks. The mice were killed at 18 weeks after the last dose of UVB. All tumors were characterized by histopathology studies. As there
was no difference between the untreated and water treated groups they were combined for comparisons with the groups treated with the various creams.
Each value is the mean±SE, and the numbers in parentheses represent percent increase. Statistical analysis was done as described in the Materials and
Methods section.
1Po0.0001, 2Po0.05, 3Pp0.01.
Table 5. Effect of topical applications of different moisturizing creams on the size of histologically characterized
tumors in high-risk SKH-1 mice previously treated with UVB light (exp. 2)
Squamous cell papillomas Keratoacanthomas Total nonmalignant tumors Squamous cell carcinomas Total tumors
Treatment
No. of
mice
Tumor volume
per mouse (mm3)
Tumor volume
per mouse (mm3)
Tumor volume
per mouse (mm3)
Tumor volume
per mouse (mm3)
Tumor volume
per mouse (mm3)
Water 30 0.6±0.5 15.3±4.2 15.9±4.3 7.4±3.5 23.2±6.6
Untreated 27 3.4±3.4 13.7±4.9 17.1±6.5 14.9±11.3 32.0±12.6
Combined control 57 1.9±1.6 14.5±3.2 16.4±3.8 10.9±5.6 27.3±6.9
Dermabase 29 0.3±0.2 15.0±3.8 15.3±3.9 29.6±22.5 44.9±23.9
(84) (3) (1) (172) (64)
Dermovan 29 2.5±1.6 23.7±6.0 26.2±5.9 25.1±12.5 51.3±14.0
(32) (63) (60) (130) (88)
Eucerin 29 2.6±2.3 24.0±8.3 26.6±9.1 14.1±10.8 40.6±16.1
(37) (66) (62) (29) (49)
Vanicream 30 3.8±2.6 32.4±9.5 36.1±9.6 7.0±5.2 43.0±11.5
(100) (123) (120) (35) (58)
Custom Blend 25 1.3 17.1±5.3 18.5±5.3 7.7±5.9 26.2±9.8
(32) (18) (13) (29) (4)
In experiment 2, female SKH-1 mice (7- to 8-week old) were irradiated with UVB (30mJ cm2) twice weekly for 20 weeks, and these tumor-free mice with
a high risk of developing skin tumors were treated topically with 100 ml of water or 100mg of different creams or ointments once a day, 5 days a week for
17 weeks. The mice were killed at 18 weeks after the last dose of UVB. All tumors were characterized by histopathology studies (Table 4) and the size of
each tumor was determined. Each value for tumor volume per mouse is the mean±SE, and the numbers in parentheses represent percent increase in size
when compared with the combined control group. None of the increases in tumor volume per mouse was statistically significant except for the increase in
tumor volume per mouse for squamous cell papillomas in the Dermovan-treated mice (Po0.05) when analyzed by a nonparametric method as described in
the Materials and Methods section.
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Studies with Custom Blend cream. Treatment of high-risk
mice topically with 100mg of Custom Blend cream once a
day, 5 days a week for 17 weeks did not have a significant
effect on the rate of increase in the percent of mice with
tumors, the number of tumors per mouse, or tumor volume
per mouse when compared with the water-treated control
group (Figure 1g).
Histology studies indicated that topical applications of the
Custom Blend cream for 17 weeks did not increase the
number of squamous cell papillomas, keratoacanthomas, or
squamous cell carcinomas per mouse when compared with
the combined control group (Table 4). Similarly, there was no
statistically significant effect of treatment with Custom Blend
cream on tumor size per mouse (Table 5).
DISCUSSION
Moisturizing creams and ointments used for the prevention
and treatment of dry skin are generally tested for safety by
determining irritant activity as well as for their effects on
sensitization (an immunological response), but skin care
preparations are generally not tested for carcinogenic activity
per se or for carcinogenic activity in animals previously
exposed chronically to UVB. Although mouse skin is widely
used for carcinogenicity studies, it should be noted that mouse
skin is much thinner and more permeable than human skin.
We have developed an animal model that resembles
sunlight-induced skin cancer in humans who receive heavy
exposure to sunlight early in life but develop skin cancer later
in life in the absence of heavy sunlight exposure. In this
albino animal model, we treat SKH-1 mice with UVB twice a
week for 20 weeks and then stop UVB irradiation. These mice
do not have tumors, but they do have a high risk of
developing skin tumors over the next several months in the
absence of further UVB irradiation (high-risk mice) (Lou et al.,
1999; Lu et al., 2002b).
During studies to determine the safety of four commer-
cially available and widely used moisturizing creams as
possible vehicles for topical chemoprevention studies, we
found that they all had tumorigenic activity when applied
topically to UVB-pretreated high-risk mice. The mechanism
of the tumorigenic effects of moisturizing creams in UVB-
pretreated mice is not known but may be by a tumor-
promoting type of mechanism that causes inflammation and
proliferation in DNA-damaged skin, and further studies on
this and other possible mechanisms are needed. During the
course of our studies, we developed a Custom Blend cream
that was not tumorigenic and was suitable for chemopreven-
tion studies in humans.
In another study with moisturizing creams or excipients in
these creams, topical applications of vasoline petroleum
jelly or lanolin before each irradiation with UVB three
times a week for 20 weeks inhibited tumorigenesis in SKH-1
mice, whereas similar applications of mineral oil enhanced
tumorigenesis (Kligman and Kligman, 1992). In addition,
topical applications of three proprietary vehicle formulations
during the course of simulated sunlight irradiation 5 days a
week for 40 weeks stimulated tumorigenesis in SKH-1 mice,
whereas another three proprietary vehicles were inactive
(Sambuco et al., 2003). Histological characterization of the
tumors was not done in either of the above two studies. It
should be emphasized that our study as well as the other
studies described here were only done in hairless SKH-1
mice, and their significance for humans has not been
established. Further studies are needed to determine the
effects of the widespread use of moisturizing creams on the
risk of sunlight-induced skin cancer in humans.
MATERIALS AND METHODS
Animals and exposure to UVB
Female SKH-1 hairless mice (6- to 7-week old) had free access to water
and were fed Purina Laboratory Chow 5001 diet from the Ralston
Purina Co. (St Louis, MO). The UV lamps used (FS72T12-UVB-HO;
National Biological Corp., Twinsburg, OH) emitted UVB (280–320nm;
75–80% of total energy) and UVA (320–375nm; 20–25% of total
energy). The studies described here were initiated under an
institutionally approved protocol for treating high risk SKH-1 mice
topically with acetone or certain chemicals in acetone once a day
5 days a week for 20 weeks. Procedures for studies in high risk SKH-1
mice treated topically with the various creams described in the present
manuscript were institutionally approved after completion of the study.
Experiments 1 and 2
In experiment 1, we treated 60 female SKH-1 mice with UVB
(30mJ cm2) twice a week for 20 weeks. These mice have a high risk of
developing skin tumors in the absence of further UVB irradiation (high-
risk mice). UVB irradiation was stopped, and half of the mice were
treated topically with 100mg Dermabase once a day, 5 days a week for
17 weeks, and the control group was untreated. Dermabase (100mg)
was applied topically by lightly rubbing (massaging) the cream into the
skin with a Q-tip. We used 3g of Dermabase per 30 mice (or
proportionately less cream for fewer mice) for each treatment session.
All of the cream was distributed evenly among the different mice and
was completely used up for each session. In experiment 1, there was no
massage control and is the reason for having both an untreated control
and a water-treated control in experiment 2 that controls for both the
stress of removing the mice from their cages and the massage.
In experiment 2, 210 female SKH-1 mice were irradiated with UVB
(30mJ cm2) twice a week for 20 weeks to obtain high-risk mice, and
UVB irradiation was stopped. The mice (30 per group) were untreated
or were treated topically with 100ml water, or with 100mg of
Dermabase, Dermovan, Eucerin Original Moisturizing Cream (Eucerin),
Vanicream, or Custom Blend cream once a day, 5 days a week for 17
weeks as described for experiment 1. The creams were massaged into
the skin with a Q-tip after each application, and similar massaging was
done in water-treated control mice. The compositions of the creams
used are described in Table 1. The formation and size of tumors were
measured throughout the 17-week treatment period in both experi-
ments 1 and 2. Tumor volume was determined by measuring the three-
dimensional size (height, length, and width) of each mass. The average
of the three measurements was used as the diameter. The radius was
determined and the volume was calculated by: volume¼ 4pr3/3. After
the 17-week treatment period, the mice were killed and dorsal skins
were taken to include each of the grossly observed masses in the treated
areas of the mice. The skins were stapled flat to a plastic sheet and
placed in 10% phosphate-buffered formalin at 4 1C for 24hours
followed by storage in ethanol until the preparation of sections of the
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epidermis and associated tumors for the histological characterization of
tumors as described earlier (Lu et al., 2002b).
Statistical analysis
For the time-course analyses, the method of Kaplan–Meier estimation
was used for the analyses of tumor-free distribution. The log-rank test
was used to test homogeneity of the tumor-free distributions among all
groups, and pair-wise comparisons of the tumor-free distributions
between any of two groups. The repeated measurement (mixed effect)
models (Lindsey, 1993; Diggle et al., 2003) without intercepts were
used in the analyses of the treatment effects on the tumor number per
mouse and tumor volume per mouse among the seven groups. The
intercepts were not included in all the models so that the tumor number
per mouse or tumor volume per mouse was zero at Day 0. The
response was the tumor number per mouse or the tumor volume per
mouse, and the covariates were time (weeks) and treatment together
with the interaction. Time was treated as a continuous variable.
Quadratic terms of time together with the interaction with treatment
were included in the analyses to account for a possible quadratic trend.
The first order autoregressive correlation structure was used for the
within-mice correlation. The treatment effects were assessed based on
the comparisons of slope (linear trend over time) of the regression lines
and/or the quadratic trend over time. If the quadratic trend over time
was not significant, it was not included in the final model. Multiplicity
adjustment was not used for comparisons between treatment groups as
this was a safety study and a conservative approach was used.
For the statistical analyses of histology studies, logistic regression
models (Kleinbaum et al., 1998) were used for the analyses of the
percent of mice with a specific type of tumor, and a Poisson regression
model (Diggle et al., 2003) was used for the analyses of the tumor
number per mouse for any tumor type. Since the tumor number per
mouse was very small for some tumor types, Poisson regression was
more appropriate in this situation. Linear regression (Kleinbaum et al.,
1998) models were used for the analyses of the total tumor volume per
mouse. Since there were no differences between water and untreated
groups for any of the analyses, the two groups were combined and
were called the control group. The comparisons of treatment groups
with control groups were performed. The multiplicities of the
comparisons were adjusted using Dunnett’s method for all the analyses.
When the normality assumption was not satisfied, a nonparametric test
based on rank (Gibbons and Chakraborti, 2003) was used for the
analyses. A 5% significance level was used for all the tests.
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